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Background: The purpose of this study is to clarify the correlations between the expression of membrane-bound
estrogen receptor-α (mERα) and epidermal growth factor receptor (EGFR) mutation and clinicopathological factors,
especially in relation to the prognosis, in patients with lung adenocarcinoma.
Methods: We conducted a retrospective review of the data of 51 lung adenocarcinoma patients with tumors
measuring less than 3 cm in diameter. Immunohistochemical staining for mERα expression and detection of the
EGFR mutation status were performed.
Results: Among the 51 patients, the tumors in 15 showed both mERα expression and EGFR mutation. ("double
positive") Significant associations between "double positive" and vascular invasion, vascular endothelial growth
factor expression, and Ki-67 expression were observed. A multivariate analysis revealed that only "double positive"
was an independent risk factor influencing the recurrence-free survival.
Conclusions: Presence of mERα expression together with EGFR mutation was found to be an independent
prognostic factor for survival in patients with lung adenocarcinoma, suggesting cross-talk between mERα and EGFR
mutation.
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Lung cancer is a leading cause of cancer-related death
worldwide. The recent increase in interest in lung cancer
appears to be attributable to the marked increase in the
global prevalence of adenocarcinoma. Especially, adeno-
carcinoma appears to have a predilection for women,
and the association of adenocarcinoma with a smoking
habit may be less than that for the other histological
subtypes of lung cancer [1,2]. These features of lung
adenocarcinoma suggest that some factors peculiar to
sex may be involved in the clinicopathology of this* Correspondence: kshimizu@med.kawasaki-m.ac.jp
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reproduction in any medium, provided the orcancer, and some preference for female-associated path-
ways in the development of this form of lung cancer.
Estrogen exerts most of its effects in breast cancer via
its receptors expressed in the tumor tissue; estrogen re-
ceptor (ER) α and ß. In breast cancer, the expression of
ERα is a useful marker that provides information on the
patient prognosis and the potential efficacy of hormone
therapy [3]. Since ER α and ß are also well known to be
expressed in both normal lung epithelial cells and lung
cancers, a possible role of estrogen has been proposed in
lung carcinogenesis [4]. Known for decades, ERα is a nu-
clear steroid receptor that is expressed in breast, ovarian,
and endometrial tissue, but antibodies used to detect
ERα in breast cancer show little or no reactivity in lung
cancer tissues. On the other hand, non-nuclear (mem-
brane-bound) ERα was described in 2002. Using thisl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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staining was found in the cytoplasm and cell membrane
[4]. This membrane-bound ERα comprises variant
isoforms that lack the amino-terminus, because they
cannot be detected by antibodies that recognize the ERα
amino-terminus. In this study, we used this antibody for
membrane-bound ERα (mERα).
The other well known female-related factor is mutation
of the epidermal growth factor receptor (EGFR). EGFR
tyrosine kinase inhibitors (EGFR-TKIs) produce a dramatic
clinical response in a significant proportion of patients with
lung cancer [5]. In 2004, response to EGFR-TKIs was
ascribed to the presence of some type of gene mutations in
the tyrosine kinase domain of EGFR [6,7]. The EGFR muta-
tions in lung cancer associated with sensitivity to EGFR-
TKIs occur more frequently in women, nonsmokers,
Asians, and with adenocarcinomas [8,9].
Estrogen directly stimulates the transcription of
estrogen-responsive genes of lung cells and transacti-
vates the EGFR pathway. Stimulation of ER has been
reported to increase the activity of the EGFR signal, and
EGFR signal increases the activity of the ER [10]. Strong
nuclear expression of ERß has been shown to be corre-
lated with the presence of EGFR mutation, and the
favorable prognostic significance of ERß expression has
been shown to be influenced by the presence of EGFR
mutation in lung adenocarcinoma [11]. However, to
date, no report has described the correlation between
mERα expression and EGFR mutation.
Based on these data from previous studies, we investi-
gated the association between the expression of mERα
and EGFR mutation in lung adenocarcinoma. In addition,
we restricted the tumor size of the adenocarcinomas to
tumors measuring less than 3 cm in diameter, because
EGFR mutation is considered an early event in the patho-
genesis of lung adenocarcinoma [12]. The purpose of this
study was to clarify the correlations between the expres-
sion of mERα and EGFR mutation and clinicopathological
factors, in relation to the prognosis of the patients. In
addition, using immunohistochemistry to determine the
expression of vascular endothelial growth factor (VEGF)
and Ki-67, we studied the tumor proliferative activity and
angiogenesis in adenocarcinomas showing mERα expres-
sion and EGFR mutation.
Methods
Study population
Fifty-one patients with lung adenocarcinoma measuring
less than 3 cm in diameter, who underwent surgical resec-
tion (lobectomy or segmentectomy) with systematic lymph
node dissection, at the Kawasaki Medical School Hospital
between 2007 and 2009 were enrolled in this study. None
of the patients had received either radiotherapy or chemo-
therapy prior to surgery. The histological diagnosis of thetumors was based on the criteria of the World Health
Organization, and the tumor, nodule, metastasis (TNM)
stage was determined according to the criteria in 2009.
Written informed consent was obtained from each patient
for the study of the excised tissue samples from the surgical
specimens. This study was conducted with the approval of
the institutional Ethics Committee of Kawasaki Medical
School. Follow-up information up to recurrence, or March
2012, was obtained from medical records.
All patients underwent fluorodeoxyglucose positron
emission tomography (FDG-PET) before the surgery. The
PET and computer tomography (CT) examinations were
performed with a dedicated PET/CT scanner (Discovery
ST Elite; GE Healthcare, Japan), at 115 minutes after intra-
venous injection of 150 to 220 MBq of 18FDG (FDGscan,
Universal Giken, Nihon Mediphysics, Tokyo, Japan). The
regions of interest (ROI) were placed three-dimensionally
over the lung cancer nodules. Semiquantitative analysis of
the images was performed by measuring the maximal
standardized uptake value (SUVmax) of the lesions.
EGFR mutation analysis
Analysis to detect EGFR mutations was performed in
the resected, paraffin-embedded lung cancer tissues by a
peptide nucleic acid-locked nucleic acid (PNA-LNA)
PCR clamp method [13]. For this study, the PNA-LNA
PCR clamp assay was performed at Mitsubishi Kagaku
Bio-clinical Laboratories, Inc, Tokyo, Japan.
Table 2 Association of membrane-bound ERα (mERα) expression / EGFR mutation status and clinicopathological
variables
mERα expression EGFR mutation
Characteristics n Negative Positive p-value Mutant Wild p-value
Patients, number 51 27 24 26 25
Age(mean), year 66.6 66.4 0.717 67.5 65.4 0.391
Sex 0.921 0.036
Male 23 12 11 8 15
Female 28 15 13 18 10
Smoking 0.615 0.124
smoker 21 12 9 8 13
never-smoker 30 15 15 18 12
Tumor size(mean), mm 20.1 23.6 0.051 24.1 19.4 0.017
PET SUVmax 4.16 8.00 0.005 4.94 5.01 0.711
Tumor differentiation 0.019 0.691
well 32 21 11 17 15
moderate/poor 19 6 13 9 10
Vascular invasion 0.001 0.006
negative 35 21 11 13 22
positive 16 3 13 13 3
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Immunohistochemical analyses were performed in the
resected, paraffin-embedded lung cancer tissues. After
microtome sectioning (4 μm), the slides were processed for
staining using an automated immunostainer (Nexes;
Ventana, Tucson, AZ, USA). The streptavidin-biotin-
peroxidase detection technique using diaminobenzidine as
the chromogen was applied. The primary antibodies were
used according to the manufacturer’s instructions (ERα:,
clone HC-20, Santa Cruz Biotechnology, Santa Cruz, CA,
1/500 dilution; VEGF:, clone A-20, Santa Cruz Biotechnol-
ogy, Santa Cruz, CA, 1/300 dilution; Ki-67: clone MIB-1,
Dako Cytomation, Kyoto, Japan, 1/100 dilution). The slides
were examined by two investigators who had no knowledge
of the corresponding clinicopathological data. The expres-
sion of each marker protein was examined and evaluated
according to the original protocol reported previously.
ERα expression was categorized into eight grades
according to previously described immunohistological
scores [14]. Initially, six degrees of the proportional scores
for positive staining were assigned according to the pro-
portion of positive tumor cells (0, none; 1, < 1/100; 2, 1/
100 to 1/10; 3, 1/10 to 1/3; 4; 1/3 to 2/3; 5, > 2/3). Next,
an intensity score was assigned, which represented the
average intensity in the tumor cells showing positive
tumor staining (0, none; 1, weak; 2, intermediate; 3,
strong). The proportional and intensity scores were then
added to obtain a total score, ranging from 0 to 8. For the
statistical analysis, ERα expression was judged as positive
when the score was≥ 4. VEGF expression was judged as
positive when more than 20% of the cancer cell cytoplasmshowed positive staining [15]. The labeling index of Ki-67
was measured by determining the percentage of cells with
positively stained nuclei. Ki-67 expression was judged as
positive when more than 10% of the cancer cell nuclei
showed positive staining [16].
Statistical analysis
Statistical analysis was performed for examining significant
differences among the groups and possible correlations be-
tween presence/absence of mERα expression/EGFR muta-
tion and the clinicopathological features using Fisher’s
exact test or the chi square (χ2) test as appropriate. An un-
paired t-test was used for comparison of the continuous
data. Multivariate analyses were performed using logistic
regression analysis. To explore the association between
recurrence-free survival (RFS) and the presence of mERα
expression/EGFR mutation, a Kaplan-Meier survival ana-
lysis was performed by stratifying significant predictor vari-
ables identified in the Cox proportional hazards model. All
the statistical analyses were conducted using SPSS software
(Version 17.0; SPSS Incorporation, Chicago, IL, USA). All
statistical tests were two-sided, and probability values
< 0.05 were regarded as statistically significant.
Results
Clinical characteristics
The characteristics of the patients are summarized in
Table 1. The patients ranged in age from 46 to 83 years
(mean, 66.8). There were 23 men and 28 women. The
median follow-up period was 34 months (range 3 to
54 months).
Figure 1 A. Kaplan-Meier curve for recurrence-free survival according to the presence or absence of membrane-bound ERα expression.
The RFS tended to be worse in patients showing elevated mERα expression level in the tumor cells than that of the patients not showing
tumor-cell mERα expression (P= 0.076, log-rank test). B. The RFS of the patients in the double-positive group was significantly worse than
that of the other patients (P= 0.003, log-rank test).
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clinicopathological characteristics
Of the 51 patients, 24 exhibited marked increase of the
immunoreactivity of the tumor cells for mERα, whereas
the remaining 27 showed no increase of mERα expres-
sion. Significant associations of the mERα expression
level in the tumor cells were observed with the tumor
differentiation grade (P= 0.019), presence or absence of
vascular invasion (P= 0.001), and the SUVmax on FDG-
PET (P= 0.005), but not with age (P= 0.717), sex
(P= 0.921), smoking status (P= 0.615) or tumor size
(P= 0.051) (Table 2). The RFS tended to be worse in
patients showing elevated mERα expression level in thetumor cells than that of the patients not showing tumor-
cell mERα expression; however, the association was not
statistically significant (P=0.076, log-rank test; Figure 1A).Relationship between the mutation status of EGFR and
the clinicopathological characteristics
Of the 51 patients, 26 had EGFR mutation, whereas the
remaining 25 had wild-type EGFR. Significant associa-
tions of the EGFR mutation status were observed with
sex (P= 0.036), tumor size (P= 0.017) and presence or
absence of vascular invasion (P= 0.006), but not with
age (P= 0.319), smoking status (P= 0.124), SUVmax on
Table 3 Relationship between membrane-bound ERα
(mERα) expression or EGFR mutation and VEGF or Ki-67
expression
mERα expression EGFR mutation
Factor Negative Positive p-value Mutant Wild p-value
VEGF
negative 17 2 <0.001 9 10 0.691
positive 10 22 17 15
Ki-67
negative 21 8 0.001 13 16 0.313
positive 6 16 13 9
Table 5 Prognostic value of recurrence-free survival























double positive Yes/ No 0.003 4.02
(1.13-14.22)
0.031
double positive: membrane-bound ERα expression positive and EGFR mutation
positive.
HR: hazard ratio.
95%CI: 95% confidence interval.
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(P= 0.691) (Table 2).
Associations of mERα expression and EGFR mutation with
VEGF and Ki-67 expression
mERα expression was significantly correlated with VEGF
expression (P< 0.001) and Ki-67 expression (P= 0.001).
However, the presence of EGFR mutation was not corre-
lated with either VEGF expression or Ki-67 expression
(Table 3).
Relationships between mERα expression, EGFR mutation
and clinicopathological characteristics
We categorized the 51 patients according to the presence







Patients, number 16 20
















positive 5 5as follows: Group-1 (n= 15): both mERα expression and
EGFR mutation (double-positive); Group-2 (n= 20): either
mERα expression or EGFR mutation (single-positive);
Group-3 (n= 16): neither mERα expression nor EGFR mu-
tation (double-negative). Significant association of the
double-positive status was observed with sex (P=0.036),
presence of vascular invasion (P< 0.001), VEGF expres-
sion (P=0.018) and Ki-67 expression (P=0.003), but not
with age (P=0.097), tumor differentiation grade (P=0.150),
SUVmax on FDG-PET (P=0.168) (Table 4). The RFS of the
patients in the double-positive group was significantly
worse than that of the other patients (P=0.003, log-rank
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grade (P=0.006), pathological stage (P=0.005) and
double-positive status (P=0.003) were independent risk
factors influencing the RFS. However, a multivariate ana-
lysis identified only double-positive status as an independ-
ent risk factor influencing the RFS (P=0.031) (Table 5).
Discussion
There have been several reports of cross-talk between
ER (ERα or ERß) and EGFR status (protein expression
or gene mutation). This is the first report focusing on
mERα and EGFR mutation. In the present study, we
found that patients with lung adenocarcinoma who had
both mERα expression and EGFR mutation showed sig-
nificantly poorer outcomes.
One of the factors peculiar to sex reported to be
involved in lung cancer development is estrogen. For
example, treatment with estrogen plus progestin in post-
menopausal women did not increase the incidence of
lung cancer, but increased the number of deaths from
lung cancer, in particular deaths from non-small-cell
lung cancer (NSCLC) [17]. ER enhances transcription in
response to estrogens by binding to estrogen response
elements and utilizing activator protein sites [18,19].
ERα exerts an augmenting effect on cell proliferation.
On the other hand, ERß exerts a suppressive effect on
cell proliferation via inhibition of ERα transcriptional ac-
tivity [20,21]. The differential roles of ERα and ß in lung
carcinogenesis and their biological properties are still
controversial. In our study, mERα expression was signifi-
cantly correlated with VEGF and Ki-67 expression.
Therefore, we suggest that mERα may exert an augment-
ing effect on angiogenesis and cell proliferation.
Some recent studies have suggested the existence of
bidirectional signaling between EGFR and ER [22,23]. In
addition, two clinical studies have suggested the exist-
ence of cross-talk between ER and EGFR. First, Kawai et
al. demonstrated that the combined overexpression of
mERα and EGFR protein in patients with NSCLC was
predictive of poorer outcomes [24]. They showed that
while overexpression of either mERα or EGFR was also
predictive of poor outcomes, combined overexpression
of mERα and EGFR was an independent prognostic fac-
tor, suggesting the existence of cross-talk between mERα
and EGFR. Overexpression of EGFR has been observed
and its prognostic significance confirmed in various
cancers. In NSCLC, Salvaggi et al. showed that overex-
pression of EGFR was correlated with a poor prognosis
[25]. However, the factor that is most strongly associated
with from EGFR-TKI therapy has been identified as
EGFR mutation, but not EGFR protein expression [9]. In
the present study, for the treatment of patients with
NSCLC, we studied EGFR mutation but not EGFR pro-
tein expression. Second, Nose et al. demonstrated thatthe favorable prognostic significance of overexpression
of ERß was influenced by the presence of EGFR muta-
tion in lung adenocarcinoma [11]. They showed that the
status of EGFR mutation did not affect the RFS, but that
ERß expression was associated with a favorable progno-
sis. To date, several studies have identified ER as a prog-
nostic factor in lung cancer. In general, ERα expression
seems to be associated with a poor prognosis, and ERß
expression with a favorable prognosis [14,24,26-28].
An important finding of the present study was that
mERα expression and the categorized status of ERα
expression/EGFR mutation was significantly correlated
with the expression of Ki-67 and VEGF. Immunos-
taining with the Ki-67 antibody is a widely accepted
method for evaluating the proliferative activity in a
variety of human tumors. Tumors showing a high ex-
pression index of Ki-67 are frequently more aggres-
sive than tumors showing a low Ki-67 expression
index [16]. On the other hand, the VEGF family of
proteins modulates angiogenesis, which is essential
for tumor growth and metastasis. Expression of VEGF
has been shown to be associated with tumor angio-
genesis, metastasis, and prognosis in several cancers,
including NSCLC [15]. To the best of our knowledge,
no reports to date have shown a correlation between
the expression of ER and VEGF or Ki-67. Our results
using tissues from patients with lung adenocarcinoma
tumors measuring less than 3 cm in diameter indicate
that double marker positivity was significantly corre-
lated with the expression of Ki-67 and VEGF.
Conclusions
This study demonstrated that the presence of mERα ex-
pression together with EGFR mutation is an independent
prognostic factor in patients with lung adenocarcinoma,
suggesting the existence of cross-talk between mERα ex-
pression and EGFR mutation.
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